Healthcare Industry News: Volcano
News Release - January 25, 2016
Opsens hires George Quinoy as Vice President / General Manager U.S. Commercial Sales & OperationsQUEBEC CITY , Jan. 25, 2016 -(Healthcare Sales & Marketing Network)- Opsens Inc. ("Opsens" or the "Company") (OPS.V) (OPSSF) is pleased to announce the hiring of George Quinoy as Vice President / General Manager U.S. Commercial Sales & Operations. He will be responsible for the U.S. commercialization of Opsens' products intended to measure Fractional Flow Reserve ("FFR"). Opsens' FFR Products, the OptoWire and OptoMonitor, are designed to optimize the diagnostic and guide treatment in patients with coronary artery disease.
George Quinoy spent 12 years in senior leadership positions including President, US & APLAC Commercial Sales and Executive Vice President, Global Sales & Operations with Volcano Corporation, which was acquired by Royal Philips for US$1.2 billion in December, 2014. Prior to Volcano Corporation, Mr. Quinoy served as the Vice President of Sales for Jomed, Inc., AVE, Inc., Medtronic AVE, Inc. and ACS/Guidant. Mr. Quinoy received a B.S. in Public Relations from the University of Florida .
"We are excited to see George, a renowned leader of the FFR industry, join us. His expertise in sales and marketing of FFR products in the U.S. will be extremely valuable given the strong potential of this market," said Louis Laflamme , President and CEO of Opsens. "With the addition of George, we now have a very experienced senior management team focused on the commercial success of OptoWire. Cases performed with the OptoWire over the last few months throughout the world confirm Opsens has a breakthrough FFR Fiber Optic Device that, we are confident, will gain market share," Laflamme added.
"I am very pleased to join Opsens at this defining moment for the Company. The success of the limited market release so far, combined with receipt of regulatory approval in the United States and the anticipated move into a new state-of-the-art facility, position Opsens to gain market share in the U.S.," said George Quinoy .
Opsens aims to become a key player in the guidewire FFR market with the OptoWire, a nitinol-based optical guidewire. The OptoWire provides intra-coronary blood pressure measurements with unique, patented optical pressure guidewire technologies. It is immune to adverse effects related to blood contact, and allows easy and reliable connectivity that leads to reliable FFR measurements in extended conditions of usage. The OptoWire is also designed to provide cardiologists with a guidewire that provides optimal performance to navigate coronary arteries and cross blockages with ease and safety. Based on industry sources, the FFR market represented more than US$300 million in sales in 2014 and is expected to reach US$1 billion in the medium-term.
About Opsens Inc. (www.opsens.com or www.opsensmedical.com)
Opsens focuses mainly on the measure of Fractional Flow Reserve ("FFR") in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities. The Company develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.